References
- Abdellatif KRA, Fadaly WAA, Kamel GM, Elshaier YAMM, El-Magd MA. 2019. Design, synthesis, modeling studies and biological evaluation of thiazolidine derivatives containing pyrazole core as potential anti-diabetic PPAR-γ agonists and anti-inflammatory COX-2 selective inhibitors. Bioorg Chem. 82:86–99.
- Al-Howiriny T, Al-Rehaily A, Pols J, Porter J, Mossa J, Ahmed B. 2005. Three new diterpenes and the biological activity of different extracts of Jasonia montana. Nat Prod Res. 19(3):253–265.
- Chen CY, Peng WH, Tsai KD, Hsu SL. 2007. Luteolin suppresses inflammation-associated gene expression by blocking NF-kappaB and AP-1 activation pathway in mouse alveolar macrophages. Life Sci. 81(23-24):1602–1614.
- Elgazar AA, Selim NM, Abdel-Hamid NM, El-Magd MA, El Hefnawy HM. 2018. Isolates from Alpinia officinarum Hance attenuate LPS-induced inflammation in HepG2: evidence from in silico and in vitro studies. Phytother Res. 32(7):1273–1288.
- Garcia-Lafuente A, Guillamo E, Villares A, Rostagno MA, Martınez JA. 2009. Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm Res. 58(9):537–552.
- Hamed A, Mohamed T, Tawfik W, Hassan E, Higgins M, El-Toumy S, Dinkova-Kostova A. 2016. Bioactive polymethoxylated flavonoids from Chiliadenus montanus. J Chem Pharm Res. 3:788–793.
- Hussein MA. 2008. Antidiabetic and antioxidant activity of Jasonia montana extract in streptozotocin-induced diabetic rats. Saudi Pharm J. 16:214–221.
- Hussein MA, Abdel-Gawad SM. 2010. Protective effect of Jasonia montana against ethinylestradiol induced cholestasis in rats. Saudi Pharm J. 18(1):27–45.
- Medzhitov R. 2008. Origin and physiological roles of inflammation. Nature. 454(7203):428–435.
- Merxmuller H, Liens P, Roesseler H. 1977. In: Heywood JB, Harborne JB, Turner BL (Eds.). The Biology and Chemistry of Compositae, p. 590. New York: Academic Press.
- Orlando BJ, Malkowski MG. 2016. Crystal structure of rofecoxib bound to human cyclooxygenase-2. Acta Crystallogr F Struct Biol Commun. 72(Pt 10):772–776.
- Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. 2008. Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 14(27):4280–4288.
- Selim NM, Elgazar AA, Abdel-Hamid NM, El-Magd MRA, Yasri A, Hefnawy HME, Sobeh M. 2019. Chrysophanol, physcion, hesperidin and curcumin modulate the gene expression of pro-inflammatory mediators induced by LPS in HepG2: in silico and molecular studies. Antioxidants. 8:371.
- Shapiro H, Singer P, Halpern Z, Bruck R. 2007. Polyphenols in the treatment of inflammatory bowel disease and acute pancreatitis. Gut. 56(3):426–436.
- Tackholm V. 1974. Students flora of Egypt, p. 562. Beirut: Cairo University.
- Triantafilou M, Triantafilou K. 2005. Invited review: the dynamics of LPS recognition: complex orchestration of multiple receptors. J. Endotoxin Res. 11(1):5–11.
- Urban MK. 2000. COX-2 specific inhibitors offer improved advantages over traditional NSAIDs. Orthopedics. 23(7 Suppl):S761–S764.
- Wang JL, Limburg D, Graneto MJ, Springer J, Hamper JR, Liao S, Pawlitz JL, Kurumbail RG, Maziasz T, Talley JJ, et al. 2010. The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life. Bioorg Med Chem Lett. 20(23):7159–7163.,